Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

The recent wave of AI innovation has fallen short of transforming commercial life sciences. In 2025, European biopharmas that ...

In his March 2023 budget, the then UK Chancellor, Jeremy Hunt, accordingly announced that from 2024 the Medicines and ...

"That's a big one," said Trump, as he was handed the WHO order to sign among dozens of others, in a signal of his ...

While there have been many significant advances in healthcare in the past 25 years, including new treatments for cancer ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

Datapharm operates the electronic medicines compendium (emc), a trusted online resource for HCPs and patients, which attracts ...

In a new white paper from Altmetric – ‘The changing landscape of journal performance measurement’ – learn how publication ...

A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...